Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43612

UPID:
OREX_HUMAN

ALTERNATIVE NAMES:
Hypocretin; Orexin precursor; Prepro-orexin; Preprohypocretin

ALTERNATIVE UPACC:
O43612

BACKGROUND:
Hypocretin, known for its alternative names such as Orexin precursor and Prepro-orexin, significantly influences the regulation of food intake and the sleep-wake cycle. Its interaction with orexin receptors underscores its role in the homeostatic regulation of energy, autonomic functions, and hormonal balance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Hypocretin could open doors to potential therapeutic strategies for Narcolepsy 1, where the orexin system's deficiency plays a crucial role. The protein's involvement in this sleep disorder underlines the importance of exploring Hypocretin-targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.